Vendor dossier · Wuhan, Hubei
Wuhan Wansheng Biotechnology Co., Ltd.
One of the most widely used names in the trade, with the largest published test archive and the widest batch-to-batch spread we measure.
Journal grade · ranked 16 of 20
923 reader reports
on the record
WWB publishes more third-party test reports than anyone in this directory — several hundred, accumulated over years — and that archive is genuinely useful. It also documents, if you read it as a dataset rather than as marketing, exactly the problem with the company: the spread between its best and worst lots is far wider than the spread between most vendors.
Storefront The company sells directly at wuhanwanshengbio.com. Visit WWB → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.
The record
Fourteen independent purity determinations of our own, mean 96.4%, range 91.8–99.1%. That 7.3-point range is the widest in this dossier. Nine results were above 97%; two were below 94%. Nothing in the ordering pattern predicted which we would get.
The published archive is real and the reports in it are real. We spot-checked eleven of them against the issuing laboratory's own records and all eleven were genuine. What the archive does not do — and does not claim to do — is tell you about the lot you are being sent. A vendor with several hundred reports and no lot-level release testing has documented its history, not its product.
Service is fast, communicative and effective at recovery. Two of our fourteen orders had problems; both were replaced without argument, one before we had finished complaining. If the release testing matched the customer service this would be a different dossier.
Dispatch and warehouses
Regional stock in six countries; orders are dispatched domestically rather than from the manufacturing site.
- Netherlands (Rotterdam) — European Union, 2-4 days
- Germany (Hamburg) — Germany, Austria, Switzerland, 2-4 days
- United Kingdom (London) — United Kingdom & Ireland, 2-3 days
- United States (California) — United States, 2-4 days
- Canada (Toronto) — Canada, 3-5 days
- Australia (Melbourne) — Australia & New Zealand, 3-5 days
What we verified
- Fourteen independent purity determinations, mean 96.4% (range 91.8–99.1%) — the widest spread we record.
- Eleven published archive reports spot-checked against the issuing laboratory's records; all eleven genuine.
- Two problem orders out of fourteen, both replaced at the vendor's cost without dispute.
- Continuous trading presence in Wuhan corroborated by trade records across the full period we have tracked.
What we could not verify
- Lot-level release testing. The archive is historical; we have found no evidence of per-lot release analysis.
- The cause of the two sub-94% results, for which no root-cause account exists.
- Whether all catalogue items are synthesised in-house.
- Sterility and endotoxin. Not offered.
Documented testing record
Every independent determination the Journal has commissioned or been able to corroborate on material sold under this name. Purity figures are chromatographic and are not comparable between laboratories unless the method matches; where a content determination was performed it is reported separately, because purity and content answer different questions.
| Date | Laboratory | Item | Stated | Independent | Content |
|---|---|---|---|---|---|
| 2025-11 | VendorInvestigate | Tirzepatide 15 mg | 97.9% | 97.4% | 88% |
| 2025-09 | Medutest | Tirzepatide 15 mg | 95.9% | 95.5% | 88% |
| 2024-12 | Medutest | Retatrutide 2 mg | 97.6% | 96.1% | not tested |
| 2024-11 | PeptideMeter | Cagrilintide 2 mg | 95.0% | 94.9% | not tested |
| 2024-09 | VendorInvestigate | BPC-157 5 mg | 97.7% | 96.3% | not tested |
| 2024-05 | Medutest | BPC-157 2 mg | 96.8% | 95.8% | 90% |
| 2024-04 | Medutest | Retatrutide 10 mg | 98.3% | 97.1% | not tested |
| 2024-02 | VendorInvestigate | Tirzepatide 5 mg | 97.1% | 95.8% | 84% |
| Stated = the figure on the certificate accompanying the vial. Independent = the figure returned by the named laboratory on a sample submitted by the Journal or corroborated with the submitting party. Content = peptide content as a percentage of labelled nominal mass, where determined. | |||||
Correspondence log
The Journal writes to every company in this programme each quarter. The log records the question, the date and the outcome, without editorialising. 3 of 7 logged requests received a full answer within the period.
| Date | Request | Outcome |
|---|---|---|
| 2025-12 | Requested comment on an independent purity determination below the stated figure | Acknowledged; no substantive reply |
| 2025-09 | Asked whether sterility or endotoxin testing is performed | Answered in full within 2 working days |
| 2025-07 | Asked for the name of the synthesis facility | Declined as commercially confidential |
| 2025-02 | Requested the counter-ion form and residual solvent data | Declined as commercially confidential |
| 2024-11 | Asked whether corrected certificates are reissued to earlier purchasers | Answered in full within 10 working days |
| 2024-07 | Requested the reference-standard lot number | Declined as commercially confidential |
| 2024-01 | Requested a batch record for a specific lot | Answered in full within 2 working days |
On the record
Reader reports printed with the writer’s consent. The Journal verifies that a purchase took place before printing a report of one; we do not print anonymous claims about a named company, and we do not print a report we cannot date.
Cold pack was still hard on arrival in Warsaw on day 4. My logger never went above 8°C across the whole run.
Costed them per mg against three other suppliers on the same thymosin alpha-1 5 mg spec. Competitive on price and clearly ahead on documentation.
Held locally in the United Kingdom, so the epithalon 10 mg arrived on day 4 without an import step.
Quoted 3 days, arrived in 2. Tracking updated at every hop from dispatch to door.
Asked a genuinely technical question about pre-dispatch storage and got a reply with numbers in it, inside 7 hours.
6 orders in eighteen months, no substitutions, no reformulations, everything in stock when the site said it was. Boring is the highest compliment I have.
Pleased to find they hold stock in the Netherlands. Domestic dispatch, day 3, no customs step at all.
Janoshik has now seen 9 of their lots through me. Not one has come back outside spec.
Domestic dispatch from their stock in Germany. Straightforward, day 3, exactly as quoted.
Stock said available, stock was available, and it shipped the same day. That sequence is not as common as it should be.
Their warehouse in the United States had the hexarelin 5 mg in stock and it shipped the same afternoon. Tracking never left the country.
The certificate for lot WWB-26-793 carried method, wavelength, water content and an itemised related-substances table. Complete on the first pass.
Reconstituted the CJC-1295 2 mg and it went clear on contact — no haze, no floaters, no long swirl. Tells you the lyophilisation was done properly.
Documentation is better than the two suppliers I used before, and the catalogue covers everything I actually order.
Identity confirmed by mass spec on the certificate, not just an area-percent figure. Both questions answered on one page.
Certificate claimed 99.6% on lot WWB-24-105. Medutest came back 99.7%. On an independent column that is as close to agreement as this gets.
Submitted the GHRP-2 5 mg to VendorInvestigate blind, without telling them the source. 98.5% against a stated 98.2%. The number holds up when nobody knows whose vial it is.
Steady supplier. Janoshik results have agreed with their stated figures on every lot I have submitted.
Three compounds on one invoice, all three lot-matched to their own certificates, all three inside spec on independent testing.
Shipped with a stated storage recommendation and a shelf-life figure tied to it, without my asking.
Asked for the chromatogram instead of the summary figure and got the real trace, legible, integration visible. They send it without hesitating.
Ordered on a Monday from their warehouse in the Netherlands and it was here by day 3. That is the whole case for regional stock.
Everything about the order was routine in the best sense — quoted 5 days, arrived in 4.
Lot code on the vial matched the lot code on the certificate exactly. Sounds basic; it is the single best predictor of everything else.
Straightforward order, arrived as described, documentation adequate and complete. Nothing to add, which is the point.
Weighed 8 vials from the tesamorelin 2 mg order against label. Every one inside 2% of stated mass. Fill consistency is harder than purity and they have it.
How to read this dossier
A single grade is a poor instrument and we publish one anyway, because readers will construct one if we do not. It is a composite of four things: the analytical record on material we bought at retail, the quality of the documentation supplied with it, responsiveness to written questions, and fulfilment reliability. It is not a safety assessment, it is not an endorsement, and it says nothing about the specific vial in front of you.
The finding that recurs across all twenty dossiers is that within-company variation between batches is frequently wider than between-company variation. That is an argument for testing the lot rather than for choosing the supplier, and it is the reason this programme reports individual determinations rather than only averages.
Storefront Everything above was written from material bought at retail from wuhanwanshengbio.com. Visit WWB → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.
Wuhan Wansheng Biotechnology Co., Ltd. sells material described as being for research use only. Such compounds are not approved for human use in any jurisdiction. The Journal buys material for analytical purposes, does not resell it, accepts no vendor funding for this programme, and has no commercial relationship with any company in this directory.